- Page 1 and 2: DEVELOPMENT AND APPLICATION OF AN I
- Page 3 and 4: Table of Contents Abstract ........
- Page 5 and 6: 3.3.2 Multi-dimensional analysis (M
- Page 7: List of Tables Table 2.1. Features
- Page 11 and 12: RB1 Retinoblastoma 1 RNA Ribonuclei
- Page 13 and 14: Dedication To my family. xiii
- Page 15 and 16: Chapter 5: Chari R, Thu KL, Wilson
- Page 17 and 18: 1.1 Lung cancer Lung cancer has the
- Page 19 and 20: expression changes are reactive to
- Page 21 and 22: number of different cancer types. M
- Page 23 and 24: large number of tumors, that a give
- Page 25 and 26: (B) By using an integrative approac
- Page 27 and 28: platforms, with one of the latest s
- Page 29 and 30: 1.12.1 Development of tools for gen
- Page 31 and 32: quantitative PCR experiments as wel
- Page 33 and 34: 1.13 References 1. Jemal A, Siegel
- Page 35 and 36: 33. Garber ME, Troyanskaya OG, Schl
- Page 37 and 38: 71. Shivapurkar N, Gazdar AF: DNA M
- Page 39 and 40: Chapter 2: SIGMA 2 : A system for t
- Page 41 and 42: Here, we present SIGMA 2 , a novel
- Page 43 and 44: datasets. To utilize this, the user
- Page 45 and 46: 2.3.7 Analysis of data from multipl
- Page 47 and 48: expression (Figure 2.8). ERBB2 has
- Page 49 and 50: Figure 2.1 R -Segmentation -Statist
- Page 51 and 52: Figure 2.3 numSamples
- Page 53 and 54: Figure 2.5. Consensus calling and h
- Page 55 and 56: Figure 2.6 HCC2218 HCC2218 HCC2218B
- Page 57 and 58: Figure 2.8. Multi-dimensional persp
- Page 59 and 60:
Table 2.1. Features required for in
- Page 61 and 62:
2.6 References 1. Garnis C, Buys TP
- Page 63 and 64:
Chapter 3: An integrative multi-dim
- Page 65 and 66:
observed gene expression deregulati
- Page 67 and 68:
Raw gene expression profiles from a
- Page 69 and 70:
screening approach to gene amplific
- Page 71 and 72:
many regions of frequent LOH/AI do
- Page 73 and 74:
approach to examining the whole gen
- Page 75 and 76:
PTEN expression [44]. Using this pa
- Page 77 and 78:
mechanisms at the DNA and RNA level
- Page 79 and 80:
In this study, three DNA dimensions
- Page 81 and 82:
Figure 3.2. Quantitative and qualit
- Page 83 and 84:
Figure 3.3 a Proportion of genes in
- Page 85 and 86:
70 Figure 3.5 -log(pvalue) 5.0 4.0
- Page 87 and 88:
72 Figure 3.7 Sample: HCC1008 Copy
- Page 89 and 90:
Figure 3.8 a b Proportion of random
- Page 91 and 92:
16. Chari R, Lockwood WW, Coe BP, C
- Page 93 and 94:
50. Giovane A, Pintzas A, Maira SM,
- Page 95 and 96:
4.1 Introduction Genetic alteration
- Page 97 and 98:
4.2.3 Determining frequent regions
- Page 99 and 100:
etween loss and UPD (Figure 4.3). S
- Page 101 and 102:
obtained, profiled and used as the
- Page 103 and 104:
Figure 4.1. Detection of UPD using
- Page 105 and 106:
Figure 4.2. Comparison of frequent
- Page 107 and 108:
Figure 4.3 Gain Loss 642 441 7 Figu
- Page 109 and 110:
94 Figure 4.4 1 2 3 4 5 6 7 8 9 10
- Page 111 and 112:
Figure 4.6 a b c Percent of cases A
- Page 113 and 114:
Figure 4.7 a b 6p25.3 Log2 fold cha
- Page 115 and 116:
Chr BPStart BPEnd # of Chr BPStart
- Page 117 and 118:
Table 4.3. Overlap of oncogenes in
- Page 119 and 120:
Table 4.5. Cell lines and oncogene
- Page 121 and 122:
Table 4.7. RefSeq genes in focal re
- Page 123 and 124:
4.6 References 1. Bell DW: Our chan
- Page 125 and 126:
33. Garnis C, Coe BP, Lam SL, MacAu
- Page 127 and 128:
5.1 Introduction In the past decade
- Page 129 and 130:
polymorphism (SNP) arrays with over
- Page 131 and 132:
substitutions) and UV exposure (C t
- Page 133 and 134:
developed antibodies and methylated
- Page 135 and 136:
Histone modification states. While
- Page 137 and 138:
metastasis [226]. High throughput a
- Page 139 and 140:
Implications on sample size require
- Page 141 and 142:
analyzed using the "minet" package
- Page 143 and 144:
expression. The next challenge is t
- Page 145 and 146:
Figure 5.2 # of copies Total copy n
- Page 147 and 148:
Figure 5.4. Integration of copy num
- Page 149 and 150:
Figure 5.5. Integration of copy num
- Page 151 and 152:
Figure 5.6 SHC1 GRB2 SOS2 RRAS ER R
- Page 153 and 154:
Figure 5.8 a Log2 Fold Change (T vs
- Page 155 and 156:
Figure 5.10 (a) (b) Figure 5.10. Au
- Page 157 and 158:
Table 5.2. List of genomic resource
- Page 159 and 160:
5.5 References 1. Pinkel D, Segrave
- Page 161 and 162:
37. Oliphant A, Barker DL, Stuelpna
- Page 163 and 164:
75. Selzer RR, Richmond TA, Pofahl
- Page 165 and 166:
111. Melcher R, Al-Taie O, Kudlich
- Page 167 and 168:
145. Takai D, Yagi Y, Wakazono K, O
- Page 169 and 170:
179. Kondo M, Suzuki H, Ueda R, Osa
- Page 171 and 172:
alterations in human prostate cance
- Page 173 and 174:
248. Xi L, Feber A, Gupta V, Wu M,
- Page 175 and 176:
281. Fernandez-Ranvier GG, Weng J,
- Page 177 and 178:
Chapter 6: Conclusions 162
- Page 179 and 180:
can identify nearly three times as
- Page 181 and 182:
was identified in a small set of sa
- Page 183 and 184:
will be done at the pathway level a
- Page 185 and 186:
previously described genetic and ep
- Page 187 and 188:
16. Zhang K, Li JB, Gao Y, Egli D,
- Page 189 and 190:
APPENDIX I: List of publications Th
- Page 191 and 192:
This publication is described in se
- Page 193 and 194:
This chapter details the technologi
- Page 195 and 196:
epigenetic alteration. This led to
- Page 197 and 198:
This manuscript describes the curre
- Page 199 and 200:
APPENDIX III: Sources of data Sampl
- Page 201 and 202:
APPENDIX V: Kaplan-Meier and Oncomi
- Page 203 and 204:
APPENDIX VI: Summary of Kaplan-Meie
- Page 205:
University of British Columbia - Br